Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study.
about
New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemiaEmerging technologies in paediatric leukaemiaCurrent concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaSmall-molecule inhibitors of the Myc oncoproteinPrognostification of ALL by CytogeneticsHow I treat acute lymphoblastic leukemia in older adolescents and young adultsCo-existence of IL7R high and SH2B3 low expression distinguishes a novel high-risk acute lymphoblastic leukemia with Ikaros dysfunctionCharacterisation of the genomic landscape of CRLF2-rearranged acute lymphoblastic leukemia.Murine B-1 B cell progenitors initiate B-acute lymphoblastic leukemia with features of high-risk disease.Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse.Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.Childhood B-acute lymphoblastic leukemia: a genetic update.Outcome of TCF3-PBX1 positive pediatric acute lymphoblastic leukemia patients in Japan: a collaborative study of Japan Association of Childhood Leukemia Study (JACLS) and Children's Cancer and Leukemia Study Group (CCLSG)Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: a report from the Children's Oncology Group.BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemiaOutcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group studySmall sizes and indolent evolutionary dynamics challenge the potential role of P2RY8-CRLF2-harboring clones as main relapse-driving force in childhood ALL.Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program.Validation of a registry-derived risk algorithm based on treatment protocol as a proxy for disease risk in childhood acute lymphoblastic leukemia.Low socioeconomic status is associated with worse survival in children with cancer: a systematic reviewIntegrated analysis of CRLF2 signaling in acute lymphoblastic leukemia identifies Polo-like kinase 1 as a potential therapeutic target.Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein.Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia.Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2.Specific expression of novel long non-coding RNAs in high-hyperdiploid childhood acute lymphoblastic leukemiaTargeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemiaRelapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome.SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia.Function of Ikaros as a tumor suppressor in B cell acute lymphoblastic leukemiaBiologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcomaMinimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: An Economic Analysis.Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia.Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features.IKZF1 deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan.Characterization of pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia with kinase fusions in Japan.What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia?Hematopoietic stem cell transplantation for children with high-risk acute lymphoblastic leukemia in first complete remission: a report from the AIEOP registry.Association of germline genetic variants in RFC, IL15 and VDR genes with minimal residual disease in pediatric B-cell precursor ALL.
P2860
Q26749177-74D6E157-50A5-464F-ADBC-49DDE2027197Q26770327-CDDED58C-0E95-487B-BC54-2C5AFB3E5191Q27025242-D9D4A36A-F235-4DF9-AC61-6BC58D326C36Q27025648-846F5607-5127-476E-995E-E6D38E9F8343Q28087446-9DCC95BF-004D-4D90-A87E-355DE5C2C50EQ28087589-607D47BB-A6EF-4AD3-B7CA-8F6510C063D9Q28276513-CE4AB375-C919-4434-86C7-5B820234A0E8Q33578333-EDA38AA7-C0E3-4059-9511-A3FB3B175960Q33638820-FD2BEB7F-4205-45C6-BD74-DCE3EB62889AQ33688248-475EE648-C226-4677-9A4A-86179308AA43Q33711119-7ED29458-451B-4149-9C0B-147D2D4234DAQ33777616-42DAD083-95D5-4D29-B509-ACF568FCAF85Q33913572-7B17B9CA-5C49-41A3-B6D3-E3A0366AA859Q33998291-CDCFB9B4-E784-4D72-9DD1-062808AB00EDQ34033206-0381B297-0ECA-43D7-8248-77A6501C0A24Q34172033-75F3D235-E94B-40D4-B901-2E9D73D14439Q34318474-0DA165DE-FF3C-4BC8-B18A-56AD79D7CFFDQ34325528-0175C221-3280-473D-AEF7-136DD285CCD1Q34475748-E55C1830-E703-4248-B954-E5774D69B25DQ34747454-D8016640-B6EE-4CF2-B37A-84C6D2A02EC5Q35107431-69C2E4E7-43AE-4FFC-8BEE-BA011482FDBCQ35572318-BE0830D2-7C57-41E5-B64A-B80A56C3D9D7Q35904943-A69FE81F-91B5-4026-8C87-0D40144EE817Q36141916-5A44F3F5-60F5-4339-AD6F-ED9DBE237D07Q36163029-BC66B807-2EA8-48C2-8689-E1D804C6EC99Q36305333-CD24C3A9-A54F-482A-A075-C3A1E38537D7Q36323903-099D81CB-58A8-40A1-821A-A5F752DE6276Q36352535-385BBCAA-09E2-4A4C-9BDB-09B7944AAC20Q36420748-0A7733B7-EE62-4FFB-BF3D-0BB1F9C3772BQ36512597-51613F35-3207-4CF1-A1BB-CD765D059714Q36562871-8FCE7ECE-7F55-41C7-A99F-C54DF0909E6AQ36717196-9B7ECF10-F083-47C3-93BA-FA2D76B0B4B9Q36731638-8631C445-ED65-418D-8B79-0ADF6D98814FQ36862511-B8B6922E-9755-4827-9EAB-C5BCC89B0CDFQ36967133-8EE04538-3306-4DC5-9B95-19590320729CQ36977450-D06A2A1A-4914-4AB3-8247-1D00282B5ADCQ37027102-077A266A-4CF9-45D6-84D1-F387747A0797Q37060647-76FB725B-FCD7-4FAE-A46E-7E4935350DEAQ37060668-4241A806-CC4E-4EBA-A951-0391EE12E34FQ37101299-603B75A7-28F6-4ECF-9103-54951470F52B
P2860
Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Outcome modeling with CRLF2, I ...... ildren's Oncology Group study.
@ast
Outcome modeling with CRLF2, I ...... ildren's Oncology Group study.
@en
type
label
Outcome modeling with CRLF2, I ...... ildren's Oncology Group study.
@ast
Outcome modeling with CRLF2, I ...... ildren's Oncology Group study.
@en
prefLabel
Outcome modeling with CRLF2, I ...... ildren's Oncology Group study.
@ast
Outcome modeling with CRLF2, I ...... ildren's Oncology Group study.
@en
P2093
P2860
P50
P1433
P1476
Outcome modeling with CRLF2, I ...... ildren's Oncology Group study.
@en
P2093
Andrew J Carroll
Bruce M Camitta
Catherine E Cottrell
Cheryl L Willman
D Jeanette Pullen
Debbie Payne-Turner
Gregory H Reaman
Huining Kang
I-Ming Chen
Julie Gastier-Foster
P2860
P304
P356
10.1182/BLOOD-2011-11-394221
P407
P577
2012-02-24T00:00:00Z